Category: ACN Newswire

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Champion Real Estate Investment Trust (Stock Code: 2778), which owns Three Garden Road and Langham Place properties, announced its annual results for the year ended 31 December 2025.HIGHLIGHTS OF THE 2025 ANNUAL RESULTS- Improved macro environment with gradual recovery in property market confidence: Benefiting from the recovery in capital markets, tourism rebound and interest rate drop, market sentiment improved in 2025, laying the foundation for commercial property recovery.- Portfolio resilience maintained: Despite the challenging operating environment with abundant office supply and shifting consumer behaviour, the Trust maintained stable occupancy rates for both office and retail properties, with Langham Place Mall maintaining a high occupancy rate of 99.3%.- Capital market recovery drives an upturn in Central office leasing activity: Leasing momentum at Three Garden Road warmed up in the second half of 2025 with site inspections increasing by 61% year-on-year. Over 75% of leases expiring in 2026 have been renewed ahead of maturity.- Proactive tenant-mix management and IP-led strategy reinforce trendsetting positioning: In 2025, Langham Place Mall strengthened its trendsetting credentials by introducing a range of trendy and lifestyle brands. Newly introduced tenants achieved sales 80% higher than previous operators, while pop-up stores tied to major marketing campaigns delivered triple-digit sales growth.- Langham Place Office Tower continues to elevate its market competitiveness: The property deepened its premier wellness hub positioning through the "6D Wellness" channel, achieving 4.6 million cumulative social media views, and pioneered Hong Kong's inaugural "Quality Service Charter" with support from over 90% of wellness tenants, further strengthening its position as an industry-leading wellness centre.- Prudent financial management: All debt facilities maturing in 2025 were successfully refinanced, and HK$1.5 billion of banking facilities have been secured for early refinancing debt due in 2026. And lower average Hong Kong Interbank Offered Rate (“HIBOR”) in 2025 resulted in meaningful interest savings.Ms. Christina Hau, Chief Executive Officer of Champion REIT, said, “2026 marks the 20th anniversary of Champion REIT, signifying an important milestone in the Trust's evolution from a single Central Grade A office asset to a diversified portfolio of landmark properties. In a challenging market environment, the Trust continues to demonstrate business resilience through prudent asset management and flexible strategic direction. Our consistent management focus is clear and targeted: while maintaining occupancy rates and enhancing income quality, we ensure financial stability. Over the past year, the Trust has made substantial progress in all these areas. Through proactive and orderly financial management, we ensure the Trust operates steadily through the current cycle."She added, "As new Central Grade A office supply is gradually absorbed by the market, supply-demand conditions are expected to stabilise from 2027 onwards. Champion REIT has established favourable conditions to capture future market recovery opportunities. Looking ahead, we will continue to play the role of ‘Super Connector’ and ‘Super Value-Adder’, fostering collaboration among tenants, partners and the community, combining innovative thinking with rigorous execution to create sustainable long-term value for stakeholders across different market environments.”Summary of financial results FY 2025FY 2024ChangeTotal Rental Income (HK$ million)1,9882,185- 9.0%Net Property Income (HK$ million)1,6131,820- 11.4%Distributable Income (HK$ million)859958- 10.4%Distribution per Unit (HK$)0.12630.1422- 11.2% 31 Dec 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)56,17960,104- 6.5%Net Asset Value per Unit (HK$)6.457.16- 9.9%Gearing Ratio25.4%23.7%+ 1.7 pp OPERATING REVIEWMarket OverviewDespite ongoing global macroeconomic volatility arising from trade uncertainties and geopolitical tensions, market sentiment in Hong Kong rebounded solidly in 2025. The recovery was supported by a strengthening stock market, steady growth in inbound tourism and an increasing number of mega-events. These improvements were further underpinned by a considerable decline in the Hong Kong Interbank Offered Rate ("HIBOR"), which boosted homeowner disposable income and lowered corporate borrowing costs.However, the operating environment for the Trust remained challenging. Abundant office supply in the market continued to weigh on market rents, while the retail market is undergoing structural adjustment due to evolving consumer behaviour and a sustained increase in outbound travel by local residents. Against this backdrop, asset quality becomes even more critical, underscoring the importance of proactively optimising the tenant mix to navigate cyclical volatility.Three Garden RoadThe leasing momentum of Central Grade A office strengthened starting the third quarter of 2025 with increasing net absorption. Demand was supported by the upswing in initial public offerings ("IPOs") and solid equity market performance with higher daily turnover. Expansion and pre-leasing commitment of sizable areas by financial institutions signalled confidence in the market outlook. The active capital market activities also created spillover effect for other sectors with notable leasing transactions of relocation and expansion from the legal sector in particular.Leasing activity at Three Garden Road strengthened in 2025. Site inspections in second half of 2025 increased by 61% year-on-year, resulting in several new tenants from the asset management and family office sectors. Occupancy remained stable at 81.6% (31 December 2024: 82.6%), with space vacated by departing occupants largely backfilled by new leases and expansions from existing tenants. Our proactive retention strategy continued to deliver results, securing renewals for over 75% of 2026 expiring leases, thereby enhancing stability and forward visibility.Langham Place Office TowerLangham Place Office continued to deepen its differentiated positioning as a premier hub for wellness and lifestyle offerings. By expanding the “6D Wellness” ecosystem, the property enhanced tenant engagement and broadened its digital reach, with the wellness channel surpassing 4.6 million cumulative views across major social media platforms. With the launch of the Social Wellness Hall, and in collaboration with the Hong Kong Retail Management Association to introduce Hong Kong’s first “Quality Service Charter” for wellness practitioners, which received support from over 90% of wellness tenants, the property further strengthened its market profile as a premium hub for wellness services.Amid a challenging office market, Langham Place Office Tower adopted a prudent yet proactive leasing strategy, continuing to attract healthcare, medical and beauty operators while fostering industry clustering and complementarities. These efforts enhanced the diversity and resilience of the tenant mix, further reinforcing the property’s positioning as a leading destination for premium wellness and healthcare services. It remains a premier choice for location-sensitive businesses, maintaining a stable occupancy rate of 86.9% (31 December 2024: 87.2%).Langham Place MallHong Kong’s retail market began to recover and gain momentum following the Golden Week in May in 2025. Supported by the influx of visitors and a vibrant calendar of mega-events, total retail sales resumed growth after more than a year of contraction. For the full year, overall retail sales in Hong Kong increased by 1.0% year-on-year, driven primarily by a 12.8% rise in online sales. Against the backdrop of evolving consumer patterns, overall sales at Langham Place Mall saw a mild adjustment. Nevertheless, proactive tenant-mix optimisation delivered strong results, with the lifestyle category recording double-digit sales growth.Marking the 20th anniversary of its opening, Langham Place Mall strengthened both leasing and marketing efforts during the year. More than 30 new brands were introduced, including the first overseas branch of Chiikawa Ramen Buta, which generated significant attention and successfully boosted footfall. Upholding the spirit of “WOW! WE PLAY”, the mall continued to advance its “Stay Local, Trend Global” strategy, leveraging year-round promotional campaigns and anniversary celebrations to reinforce its leadership position as a trendsetting retail destination. Occupancy remained high at 99.3%.New tenants surpassed previous operators by an average of 80% in sales, while pop-up stores tied to major marketing campaigns achieved triple-digit sales growth, reflecting the strong synergy between brand partnerships and content-driven activations. In addition, the introduction of themed experiences and designer events on Levels 9 to 12 successfully revitalised historically lower-traffic floors, stimulating cross-floor spending, enhancing spatial efficiency, and generating incremental non-traditional revenue. These initiatives have enabled the mall to demonstrate sustained resilience and competitiveness amid a rapidly evolving retail landscape.SustainabilityThe Trust continued to embed sustainability deeply into its asset management strategy, with a strong focus on environmental stewardship, health and well-being, and community engagement. We achieved the highest five-star rating in the GRESB Real Estate Assessment for the third consecutive year and attained an “AA+” rating in the Hang Seng Corporate Sustainability Benchmark Index, reaffirming our leadership in sustainable practices.At Three Garden Road, the successful implementation of an AI-optimised chiller plant system delivered an annual energy savings of 6.1%. In parallel, we worked closely with tenants to advance the EcoChampion Pledge, fostering collective action in energy efficiency, waste reduction and green procurement.In addition, guided by our “6D Wellness” framework, we rolled out a range of community collaboration programmes to support the physical, mental and social well-being of tenants and visitors. These initiatives underpin our commitment to creating long-term value for all stakeholders.OutlookLooking ahead, while uncertainties in the global macroeconomic environment remain, market sentiment in Hong Kong is expected to improve gradually, supported by the resilience of capital markets and the recovery of inbound tourism, which will in turn provide support for office demand and local consumption. We remain cautiously optimistic about the operating environment in Hong Kong. While there are still market challenges, Champion REIT is well positioned to capture emerging opportunities. We will continue to adhere proactive asset management strategy to deliver long-term value for our stakeholders. About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB for three consecutive years since 2023.Website: www.championreit.comFor press enquiries:Jervois FinanceKenneth TangTel: 9827 2880Email: kenneth.tang@jervoisfinance.comAda LauTel: 9506 6017Email: ada.lau@jervoisfinance.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月26日 - (亞太商訊 via SeaPRwire.com) - 2月13日，聯想控股（03396.HK）旗下君聯資本所投產業級AI智能體龍頭企業海致科技（02706.HK）在香港聯交所成功上市。海致科技成立於2013年，專注於通過圖模融合技術，開發Atlas圖譜解決方案及產業級智能體，並提供產業級人工智能解決方案。公司依託自主可控的高性能圖計算核心技術，致力於為大語言模型提供準確、可追溯、可解釋的知識增強，有效解決AI幻覺問題，推動企業級AI應用的規模化落地。海致科技是國家高新技術企業，獲得近百項知識產權。公司總部位於北京，在深圳、上海設有研發中心，業務已覆蓋全國26個省級行政單位，服務超過360家客戶，涵蓋金融、能源、智能製造、交通、醫療、公共服務等領域的百余個應用場景。根據弗若斯特沙利文報告，按2024年營業收入計算，海致科技在中國產業級AI智能體提供商中排名第五，並在以圖為核心的AI智能體細分市場中佔據約50%的份額，穩居第一。公司也是行業內首家通過知識圖譜有效減少大模型幻覺的企業。海致科技構建了以"圖計算能力"、"圖模融合技術"和"多行業應用專長"為核心的技術壁壘，自主研發的AtlasGraph圖數據庫曾打破世界性能紀錄。招股書顯示，該公司已積累近百項知識產權，其全棧解決方案在反欺詐、智能營銷、風險識別、數據治理及智能製造等多類場景中實現落地，並展現出強大的產業賦能價值。君聯資本於2016年、2019年、2020年、2023年先後用美元和人民幣五只基金持續投資海致科技，並成為公司最大的機構股東，堅定支持了其從可視化軟件和知識圖譜，到圖數據庫基礎軟件和企業數智化AI賦能平台，再發展成為基於新一代生成式大模型和圖模孿生的、中國領先的產業AI基礎設施供應商。投資後，君聯資本充分發揮在科技領域的產業生態資源，在海致科技戰略定位、人才組織建設、重點行業拓展等方面提供了持續支持，助力公司夯實技術領先性並加速商業化進程。君聯資本總裁李家慶表示：海致科技的成功上市，標誌著其在圖計算與AI融合的產業級賽道中已建立起顯著的領跑優勢。憑藉原創的圖模融合技術，海致科技有效破解了大模型在企業關鍵場景中"不敢用、不好用"的落地難題，為企業提供了可信、可靠、可落地的智能化引擎。期待海致科技以上市為契機，持續深化技術融合、拓展行業生態，成為推動中國產業智能化轉型的核心力量，為千行百業的數字化轉型與效率提升貢獻力量。君聯資本對全球人工智能技術驅動的新趨勢、新機遇高度關注，積極佈局"人工智能+"，重點關注以下幾個投資方向：第一是人工智能應用，如具身智能、AI+金融、AI+教育，以及AI賦能的各類終端產品和服務；第二是人工智能大模型產業，包括基座大模型和行業/垂類大模型；第三是人工智能基礎設施，包括人工智能晶片、智能計算平台和數據/工具等方向。近年來，君聯資本通過現有基金組合及資金端生態協同，在人工智能產業生態的基礎設施層、模型和技術層、應用層，共計投資了超過70家企業，包括科大訊飛（002230.SZ）、智譜華章（02513.HK）、昆侖芯、無問芯穹、自變量機器人、實在智能等。在"人工智能+"領域，君聯資本長期圍繞"大難長"方向進行科創佈局，並持續深耕，致力於構建貫通自主創新、產業鏈生態構建與科技金融服務的"新質創投樣本"。來源：君聯資本微信公眾號、聯想控股微空間 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 26, 2026 - (ACN Newswire via SeaPRwire.com) – Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced the successful delivery of the first prototype of the FLOKI Minibot M1, an AI-powered companion robot developed in collaboration with Rice Robotics Holdings Limited (“Rice Robotics”). This milestone marks the Group’s official entry into the fast-growing consumer robotics (B2C) market, as part of its broader strategy to diversify its business operations.The FLOKI Minibot M1 is engineered to serve as an intelligent daily companion, blending a personality-driven AI with practical functionalities. These include smart reminders, proactive notifications, natural and engaging conversation, concierge services, and educational tutoring. The robot is designed to distinguish itself in the market through its capacity to develop a personalized interaction style with each user, delivering a more intuitive and engaging experience than certain existing companion robotic products.Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint commented: “We are immensely proud of the progress achieved with the FLOKI Minibot M1. Its delivery marks a significant step forward in our strategic entry into the B2C robotics market. Consumer demand for AI-powered companions is accelerating rapidly, and we believe the FLOKI Minibot M1 is uniquely positioned to meet this need by integrating advanced AI-driven features with a deeply engaging and personalized user experience.”The launch of the FLOKI Minibot M1 strategically positions Mint to capitalize on the exceptional growth of the AI robotics market, particularly within the Asia Pacific region. Future development roadmaps for the FLOKI Minibot M1 include enhancements tailored for the education, hospitality, and entertainment sectors, further broadening its commercial potential, subject to further research, development and commercialization efforts.The prototype was co-developed by the R&D team at Axonex Intelligence Limited, Mint's wholly-owned subsidiary, and Rice Robotics Limited, a renowned player in the delivery robotics sector. This partnership leverages Mint's robust expertise in robotics R&D with Rice Robotics' market-tested vision for integrated AI solutions. The first prototype was proudly showcased at the British Education Training and Technology Show in the U.K. in early 2026. Axonex and Rice Robotics have formalized their collaboration with an agreement to deliver up to 800 FLOKI Minibot M1 units by the end of the first quarter of 2026. Mint and certain investors have agreed in principle to increase their total proposed investment from HK$10 million to HK$15 million for the formation of the proposed strategic joint venture with Rice Robotics Holdings Limited, subject to definitive documentation and customary closing conditions.Mr. Chan added, "This milestone is a testament to Mint's dedication to innovation and value creation. Our successful collaboration with Rice Robotics empowers us to deliver solutions that fundamentally enhance how people interact with technology in their daily lives. As we scale production and expand our market presence, we are confident that the FLOKI Minibot M1 will become a cornerstone of our robotics portfolio, driving top-line growth and delivering long-term value for our shareholders."The introduction of the FLOKI Minibot M1 aligns with Mint's overarching strategy to seize opportunities within the expanding "Physical AI" market—intelligent systems that harmoniously integrate hardware and software to operate autonomously in real-world environments. With the FLOKI Minibot M1 progressing toward commercial release and a robust pipeline of next-generation robotics solutions, Mint is well-positioned to thrive in the rapidly growing Asia Pacific AI robotics market while continuing to develop its capabilities in innovation and technology.Photo CaptionThe first prototype of AI-Powered Companion, FLOKI Minibot M1, was proudly showcased at the British Education Training and Technology Show in the U.K. in early 2026.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Axonex Intelligence Limited, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.Rice Robotics Holdings LimitedRice Robotics Holdings Limited is a renowned leader in autonomous delivery robot solutions, with a strong market presence across Asia. The company specializes in the design, development, and deployment of intelligent robotic systems for logistics and service industries. Its core technology platforms serve high-profile clients in Japan, demonstrating proven reliability in complex operational environments. With a focus on innovation and real-world application, Rice Robotics is committed to transforming last-mile delivery and service automation, enhancing operational efficiency and redefining customer experiences.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company's filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月26日 - (亞太商訊 via SeaPRwire.com) - Mint Incorporation Limited（「Mint」或「集團」，納斯達克股票代碼：MIMI）─ 一家專注於人工智能與機械人技術，同時提供商業室內設計及裝修服務的香港本土企業，今日欣然宣布成功交付與Rice Robotics Holdings Limited（「Rice Robotics」）共同研發的人工智能（AI）陪伴機械人FLOKI Minibot M1的首台原型機。這一里程碑標誌著集團正式進軍快速增長的消費級機械人（B2C）市場，作為其業務多元化發展策略的一部分。FLOKI Minibot M1是一款智能日常夥伴，兼具AI 驅動的個性化特質和實用功能。這些功能包括智能提醒、主動通知推送、自然對話、禮賓服務，以及教育輔導。該機械人的獨特之處在於其能夠與每位用戶培養個性化的互動風格，提供比某些現有的陪伴機械人產品更直觀和互動的體驗。Mint董事會主席兼行政總裁陳海龍先生表示：「我們對FLOKI Minibot M1項目取得的進展感到非常自豪。該產品的交付是我們戰略性進入B2C機械人市場的重要一步。消費者對AI陪伴的需求正在迅速增長，我們相信FLOKI Minibot M1獨特的定位在於將先進的 AI 驅動功能完美結合深度互動且個性化的用戶體驗，以滿足這一需求。」FLOKI Minibot M1的推出戰略性地使Mint能夠充分利用AI機械人市場，尤其是亞太區市場的卓越增長。FLOKI Minibot M1未來的發展路線方向包括針對教育、酒店款待及娛樂行業的定製化升級，進一步拓展其商業潛力。相關發展將視乎後續的研發及商業化進程而定。原型機由Mint全資子公司Axonex Intelligence Limited的研發團隊，與送貨機械人領域知名企業Rice Robotics共同開發。此合作結合了Mint在機械人研發方面的深厚專業知識，以及Rice Robotics在綜合AI方案方面經過市場驗證的願景。首個原型機已於2026年初在英國舉行的英國教育科技博覽會（British Education Training and Technology Show）中隆重亮相。Axonex與Rice Robotics已正式達成合作協議，計劃於2026年第一季度末交付多達800個FLOKI Minibot M1。此外，Mint及其若干投資者已原則上同意，將與Rice Robotics Holdings Limited組建策略合營企業的建議總投資額，由1,000萬港元增加至1,500萬港元，有關投資將視乎最終文件簽署及慣常交割條件的達成而定。陳先生補充道：「這一里程碑彰顯了Mint對創新與價值創造的堅定承諾。與Rice Robotics的成功合作，使我們能夠提供從根本上提升人們日常科技互動體驗的解決方案。隨著我們擴大生產規模並拓展市場版圖，我們深信FLOKI Minibot M1將成為我們機械人業務組合的重要基石，帶動營收成長並為股東創造長期價值。」FLOKI Minibot M1的推出，與Mint把握「實體AI」（Physical AI）市場機遇的整體戰略契合。該領域專注於開發能將硬件與軟件和諧融合、從而在現實環境中自主運作的智能系統。隨著FLOKI Minibot M1穩步邁向商業化發布，加上正在籌備中的嶄新機械人解決方案，Mint集團已做好準備，在快速增長的亞太區AI機械人市場中蓬勃發展，同時持續提升自身在創新與科技領域的實力。AI陪伴機械人FLOKI Minibot M1首個原型機已於2026年初在英國舉行的英國教育科技博覽會中隆重亮相。有關Mint Incorporation LimitedMint Incorporation Limited（納斯達克股票代碼：MIMI）是一家於納斯達克上市的香港本土企業，專注於人工智能、機械人技術及室內設計領域。透過其子公司 Axonex Intelligence Limited，公司為企業、地產、商場、政府機構等提供智能機械人與設施管理解決方案。Mint 同時營運 Matter International Limited，提供專業室內設計與裝修服務。秉持創新與實際應用並重的理念，Mint 致力於提升各行各業的效率、安全性與生活質素。有關Rice Robotics Holdings LimitedRice Robotics Holdings Limited 是亞洲市場領先的自動配送機械人解決方案供應商，在區內具有顯著的市場影響力。公司專注於為物流與服務行業設計、開發及部署智能機械人系統。其核心技術平台服務於日本多家知名客戶，在複雜營運環境中展現出卓越的可靠性。Rice Robotics 致力於推動最後一哩配送與服務自動化轉型，透過創新與實際應用提升營運效率，重塑用戶體驗。前瞻性陳述 本新聞稿中的某些陳述屬於前瞻性陳述。這些前瞻性陳述涉及已知和未知的風險和不確定性，並基於公司對可能影響其財務狀況、營運成果、業務策略和財務需求的未來事件的目前期望和預測。投資者可通過「大約」、 「相信 」、 「希望 」、 「期望 」、 「預期 」、 「估計 」、「項目 」、 「打算 」、 「計劃 」、 「將 」、 「將會 」、 「應該 」、 「可能 」或其他類似的詞語或短語識別這些前瞻性陳述。公司不承擔更新或修訂任何前瞻性陳述以反映隨後發生的事件或情況，或其期望的變化的公開義務，除非法律要求。儘管公司認為這些前瞻性陳述所表達的期望是合理的，但無法保證這些期望將會被證實正確，並提醒投資者實際結果可能與預期結果有顯著差異，並鼓勵投資者查閱可能影響其未來結果的其他因素，這些因素披露在公司向證券交易委員會提交的文件中。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

資源估算亮點：經測定礦產資源量為 2.72 億噸（Mt），指示礦產資源量為 3.37 億噸（Mt），推斷礦產資源量為 5.03 億噸（Mt），按 0.2% 銅當量（CuEq）邊界品位計算，或2.72 億噸經測定礦產資源（Mt），按所含金屬量表示，總計為 26.1 億磅（Blb）銅當量（CuEq），品位為 0.44% CuEq，其中包括 11.1 億磅銅、3,560 萬磅（Mlb）鈷、141 萬盎司（Moz）黃金，以及 217 萬盎司（Moz）白銀。（表 1）3.37 億噸指示礦產資源（Mt），按所含金屬量表示，總計為 32.1 億磅（Blb）銅當量（CuEq），品位為 0.43% CuEq，其中包括 13.1 億磅銅、4,450 萬磅（Mlb）鈷、181 萬盎司（Moz）黃金，以及 288 萬盎司（Moz）白銀。（表 1）5.09 億噸推斷礦產資源（Mt），按所含金屬量表示，總計為 45.7 億磅（Blb）銅當量（CuEq），品位為 0.41% CuEq，其中包括 17.2 億磅銅、6,620 萬磅（Mlb）鈷、277 萬盎司（Moz）黃金，以及 419 萬盎司（Moz）白銀。（表 1）鈧資源：該礦床在經測定及指示類別中擁有 6.09 億噸（Mt）（含約 17,510 噸鈧），在推斷類別中擁有 5.04 億噸（Mt）（含約 14,465 噸鈧）。鈧已納入礦產資源估算，在當前加工限制條件下，僅限於使用內部產生的酸處理尾礦的 12.5%。鈧資源估算為經測定及指示類別 7,600 萬噸（Mt），品位 28.8 克/噸（g/t）Sc（含 2,189 噸鈧），以及推斷類別 6,300 萬噸（Mt），品位 28.7 克/噸（g/t）Sc（含 1,808 噸鈧）。加拿大不列顛哥倫比亞省溫哥華, 2026年2月26日 - (亞太商訊 via SeaPRwire.com) - Doubleview Gold Corp（TSXV: DBG）（OTCQB: DBLVF）（FSE: 1D4）（“Doubleview”或“公司”）欣然宣佈更新其位於不列顛哥倫比亞省西北部、由公司 100% 持有的多金屬 Hat 斑岩項目（Hat）的礦產資源估算（MRE）。Hat 項目富含銅、金、鈷和銀，以及鈧，使其成為重要的關鍵礦產資源來源。Doubleview Gold Corp 總裁兼首席執行官 Farshad Shirvani 表示：“通過極具針對性的鑽探工作，該礦床規模逐年擴大，目前已擴展至約 1.6 公里 × 1.6 公里的範圍。我感謝我們的技術團隊和管理團隊在這一過程中所做的努力。我們在 Hat 礦床中還發現了多種其他元素，這些成果將很快公佈，進一步彰顯該礦床的獨特性並提升資源價值。”Hat 礦床礦產資源估算（MRE）摘要：表 1：Hat 礦床在 0.2% CuEq 邊界品位下的礦產資源估算（生效日期為 2026 年 2 月 4 日，技術報告中將採用的基準情景）礦產資源分類噸位（Mt）平均品位金屬含量銅當量（%）銅（%）金（克/噸）鈷（%）銀（克/噸）銅當量（十億磅）銅（十億磅）金（百萬盎司）鈷（百萬磅）銀（百萬盎司）經測定2720.440.220.180.0080.372.611.111.4135.62.17指示3370.430.210.190.0080.393.211.311.8144.52.88測定+指示合計6090.430.210.180.0080.385.822.423.2280.15.05推斷5030.410.180.190.0080.384.571.722.7766.24.19表 2：截至 2026 年 2 月 4 日，Hat 礦床在 0.2% CuEq 邊界品位下的礦產資源估算——氧化鈧資源礦產資源分類噸位（Mt）鈧噸位¹（Mt）平均品位 Sc（克/噸）金屬含量 Sc₂O₃²（噸）經測定2723428.791,081指示3374228.761,334測定+指示合計6097628.772,415推斷5036328.691,996註釋：1 鈧噸位按各資源類別中礦化物料的 12.5% 計算，該比例反映在當前冶金設計限制條件下，預計將通過專用鈧浸出回路進行處理的尾礦佔比。2 氧化鈧金屬含量的計算採用 72% 的冶金回收率，以及從 Sc 轉換為 Sc₂O₃ 的 1.534 轉換係數。Mineit 的合資格人士 Tomasz Wawruch（FAusIMM）完成了本次礦產資源估算（MRE），並已審閱和批准本新聞稿中與 MRE 相關的技術披露內容。Wawruch 先生為獨立於 Doubleview 的高級地質及礦產資源顧問。ARSENEAU Consulting Services Inc. 的 Gilles Arseneau 博士（PhD., P.Geo.）對本次 MRE 提供了獨立審查。礦產資源並非礦石儲量，尚未證明具有經濟可行性。礦產資源估算可能會受到環境、許可、法律、產權、稅收、社會政治、市場或其他相關因素的重大影響。推斷礦產資源在地質上被認為過於推測性，無法進行經濟性分析，因此不能歸類為礦石儲量。本次礦產資源估算依據加拿大採礦、冶金與石油學會（“CIM”）《礦產資源與礦石儲量定義標準》（2014 年）及 CIM 礦產資源與礦石儲量（MRMR）最佳實踐指南（2019 年）編製。本次 MRE 的生效日期為 2026 年 2 月 4 日。金屬含量採用以下冶金回收率計算：銅（Cu）= 85%，金（Au）= 89%，鈷（Co）= 78%，銀（Ag）= 68%。所採用的經濟假設包括：銅 US$4.80/磅，鈷 US$20.00/磅，金 US$3,200/盎司，銀 US$46/盎司，以及 2% 的淨冶煉收益（NSR）特許權使用費。礦產資源在優化露天採坑約束範圍內並按 0.2% CuEq 邊界品位報告，基於每噸磨礦處理成本 C$7.93、每噸磨礦一般及行政成本 C$2.90，以及採礦成本 C$3.01/噸；此外，低於 1,125 米參考水平（mRL）的每一採台，採礦成本將按每噸增加 C$0.015 遞增計算。CuEq 計算不包括鈧。用於計算 CuEq 的公式為： CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85)) / (4.8 × 22.0462 × 0.85)]，其中所有輸入變量均以 ppm 表示，CuEq 以百分比（%）表示。由於四捨五入，個別數值與總數之間可能存在輕微差異；該等差異不被認為對本次 MRE 具有實質性影響。礦產資源分類反映地質可信度水平，並滿足勘探及資源開發階段相應的不確定性標準。為將不確定性降低至生產規劃所需水平，仍需進行額外鑽探。本次 MRE 反映了建模時可獲得的地質解釋、鑽孔間距及估算參數。任何新增鑽探預計將通過提高估算可信度及優化礦化體幾何形態，從而對當前結果產生影響。礦產資源結果以原位形式呈現於優化露天採坑範圍內。採坑範圍之外的礦化物料未納入當前 MRE 統計。計算採用公制單位（米、噸、克/噸）。共有 97 個金剛石鑽孔（岩芯總長度 49,548 米）納入礦產資源估算。所有用於 MRE 的鑽探數據在納入前均經過標準 QA/QC 質量保證與質量控制驗證。區塊模型以 UTM 第 9N 帶 346,750 E / 6,453,000 N / 0（NAD83）為模型原點進行定義。母區塊尺寸為 15 × 15 × 15 米，總計 136 × 150 × 75 個區塊，覆蓋範圍分別為 X 方向 2,040 米、Y 方向 2,250 米及 Z 方向 1,125 米。所有體積及估算結果均受上述離散化參數約束。圖 1：海拔 715 米（ASL）處的區塊模型平面圖，顯示優化 120 千噸/日（kt/d）露天採坑殼體範圍內銅當量品位的分佈情況（UTM 第 9N 帶［NAD 83］）圖 2：沿東向 348000 剖面向西觀察的區塊模型剖面圖，顯示優化 120 kt/d 露天採坑殼體範圍內銅當量品位的分佈情況（UTM 第 9N 帶［NAD 83］）圖 3：海拔 715 米（ASL）處的區塊模型平面圖，顯示 120 kt/d 優化露天採坑殼體範圍內銅當量分類的分佈情況（UTM 第 9N 帶［NAD 83］）圖 4：沿東向 348000 剖面向西觀察的區塊模型剖面圖，顯示 120 kt/d 優化露天採坑殼體範圍內銅當量分類的分佈情況（UTM 第 9N 帶［NAD 83］）Hat 礦床Hat 礦權項目由 16 個礦業權組成，覆蓋不列顛哥倫比亞省西北部 Golden Bear 礦山公路以北共 13,823.09 公頃土地。更多資訊請訪問 [www.doubleview.ca。](http://www.doubleview.ca。)Mineit Consulting Inc（Mineit）依據《CIM 礦產資源與礦石儲量定義標準》編製了本次礦產資源估算（MRE）。支持本次 MRE 的技術報告將在 45 天內提交至 SEDAR+（[www.sedarplus.ca）。](http://www.sedarplus.ca）。)Mineit 的 Tomasz Wawruch（FAusIMM）為本次 MRE 的合資格人士（Qualified Person），並已審閱和批准本新聞稿中與 MRE 相關的技術披露內容。Wawruch 先生為獨立於 Doubleview 的地質與礦產資源顧問。ARSENEAU Consulting Services Inc. 的 Gilles Arseneau 博士（PhD., P.Geo.）對本次 MRE 進行了獨立同行評審，未發現 Tomasz Wawruch 編製的資源模型存在任何重大缺陷。關於 Hat 項目的冶金研究，Magister Metallurgy 的 EUR ING Andrew Carter（B.Sc., CEng., MIMMM QMR, MSAIMM SME）為 Doubleview 根據《國家文書 43-101 礦業項目披露標準》所定義的合資格人士；其已審閱並批准本新聞稿的技術內容。Carter 先生獨立於 Doubleview。關於Doubleview Gold CorpDoubleview Gold Corp是一家總部位於加拿大不列顛哥倫比亞省溫哥華的礦產資源勘探和開發公司，其股票在多倫多證券交易所創業板（TSX-Venture Exchange）上公開交易（TSXV：DBG），（OTCQB：DBLVF），（GER：A1W038），（FSE：1D4）。Doubleview專注於識別、收購和資金支持北美特別是不列顛哥倫比亞省的貴金屬和基本金屬勘探項目。Doubleview通過收購和勘探高質量的金、銅和銀礦產，並應用先進的最新勘探方法，增加股東價值。公司的戰略性物業組合提供了分散化並減輕了投資風險。董事會代表, Farshad Shirvani, 總裁兼首席執行官欲瞭解更多資訊，請聯絡：Doubleview Gold Corp Vancouver, BCFarshad Shirvani 總裁兼首席執行官Institutional Line: (604) 607-5470電話: (604) 678-9587電郵: corporate@doubleview.ca多倫多證券交易所創業板（TSX VENTURE EXCHANGE）及其監管服務提供者（根據多倫多證券交易所政策的定義）對本發布內容的充分性或準確性不承擔責任。本文中部分所作的聲明和包含的資訊可能構成“前瞻性資訊”。特別是關於私募和未來工作計劃的參考，或對此類工作計劃的質量或結果的期望，都受到與物業運營、勘探活動、設備限制和可用性以及其他我們目前可能不了解的風險有關的風險。因此，建議讀者不要過度依賴前瞻性資訊。除適用的證券法規要求外，公司不承擔公開更新或修訂前瞻性資訊的義務，無論是因為新資訊、未來事件還是其他原因。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Reno, Nevada--(ACN Newswire via SeaPRwire.com - February 25, 2026) - Executive Agility, a boutique consultancy specializing in IPO readiness, governance and multi-stakeholder project management for effective capital markets execution, today announced a strategic collaboration with DealMaker, a leading online capital-raising platform that powers online capital (ie: Regulation A) for emerging companies right through to IPO. The collaboration gives global growth and pre-IPO companies targeting listings on U.S. and Canadian stock exchanges - such as TSX, TSXV, CSE, U.S. national exchanges, SEC-registered offerings, and OTC markets - access to a self-directed, tech-enabled capital-raising channel that complements traditional investment banking and underwriting.A Digital, Self-Directed Capital-Raising Path that Complements Investment BanksThrough this collaboration, Executive Agility will integrate DealMaker's digital capital-raising infrastructure into its IPO readiness and governance services, enabling issuers to run online Regulation A, Regulation CF, and Regulation D campaigns while also working with investment banks and underwriters on traditional offerings. These exempt offerings can be sequenced before or alongside underwritten IPOs, uplists, or other SEC-registered transactions, allowing issuers to validate investor demand, build investor communities, and strengthen their capital structure ahead of a listing."IPO-bound and dual-listing companies want more control over their capital-raising journey while still leveraging the strengths of investment banks and underwriters," said Deb Banning, CEO and Founder of Executive Agility. "By combining Executive Agility's IPO readiness, governance benchmarking, and capital markets execution expertise with DealMaker's digital capital-raising platform, we provide issuers with a coordinated, complementary set of tools to raise capital, de-risk execution and move faster toward listing on U.S. and Canadian exchanges.""Our mission is to give founders and executives a digital, compliant way to raise capital on their own terms, from early growth through IPO," said Rebecca Kacaba, co-founder and CEO of DealMaker. "Working alongside Executive Agility's IPO readiness and governance advisory services - and within a broader ecosystem of global exchanges - we help issuers utilize flexible, compliant offerings in a way that perfectly complements traditional investment banking, rather than competing with it."Executive Agility Facilitates Cross-Border Capital Markets TransactionsExecutive Agility's IPO and listing readiness services routinely assist issuers pursuing listings, uplistings, or dual / cross-listings on the CSE, NSX and other North American and international exchanges, within integrated U.S.-Canada-Australia capital markets strategies.Executive Agility enables issuers to:Engage key capital markets participants to secure growth and pre-IPO funding for upcoming IPOs, RTOs, uplistings, and exchange transitions in the U.S. and Canada.Pursue dual listings, cross-listings, and uplistings on CSE, TSX / TSXV, U.S. exchanges, OTCQX / OTCQB, and NSXAAlign governance, disclosure, and execution with SEC, Canadian, and other regulatory standardsCoordinate governance benchmarking, disclosure readiness, and execution oversight to satisfy public-market requirements during capital raisingEnd-to-End IPO Readiness, Governance and Capital Markets ExecutionExecutive Agility operates as the execution and coordination layer between issuers, boards, underwriters, legal counsel, auditors, regulators, and other advisors, ensuring companies are not only technically eligible to list, but genuinely ready to operate as public companies. The firm's services include IPO and listing readiness assessments, governance benchmarking, disclosure and continuous reporting frameworks, multi-party stakeholder coordination, and leadership deployment to stabilize organizations during change and transactions.By adding DealMaker as a preferred digital raising platform within its curated Professional Network, Executive Agility now offers IPO readiness and capital-raising clients:A flexible, tech-driven capital-raising channel (Reg A, Reg CF, Reg D) that can be used pre-IPO, between rounds, and post-listing alongside underwritten offerings.Faster, more predictable IPO and listing timelines through structured project management, governance remediation, and integrated capital markets execution across U.S., Canadian, and cross-border markets.A coordinated, white-glove approach that reduces transaction and execution risk and improves the quality of filings and investor communications across the IPO and listing lifecycle.About Executive AgilityExecutive Agility serves as the strategic quarterback for the IPO and listing process, providing global growth companies with a rapid, coordinated and cost-effective path to market success. The firm specializes in IPO readiness, governance transformation and executive deployment for issuers targeting the TSX, TSXV, CSE, U.S. national exchanges and OTC markets.As the essential execution layer between issuers, boards, underwriters, legal counsel and regulators, Executive Agility ensures organizations are not only technically eligible to list but genuinely prepared to operate as sophisticated public companies. By integrating a turnkey professional network with modern digital capital-raising tools, we reduce transaction risk, accelerate timelines and reduce costs. Executive Agility empowers growth-stage companies to navigate the complexities of U.S., Canadian and cross-border capital markets with speed, institutional-grade discipline and confidence.About DealMakerHeadquartered in New York City, DealMaker is the future of capital raising. With more than $2.4 billion raised, DealMaker's platform enables companies to own their end-to-end capital raising lifecycle—from investor acquisition and conversion to compliance, payments, and engagement. Its white-label approach allows companies to retain ownership of their data and investor relationships while building lasting investor communities around their brands. For more information, visit dealmaker.tech.Media Contact - Executive AgilityDeb BanningChief Executive Officerinfo@executive-agility.comMedia Contact - DealMakerChris DeLucapress@dealmaker.techTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/285279 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Resource estimate highlights:Measured Mineral Resources of 272 million tonnes (Mt), Indicated Mineral Resources of 337 Mt, and Inferred Mineral Resources of 503 Mt at a 0.2% copper equivalent (CuEq) cut-off grade, or272 Mt of Measured Mineral Resources, expressed in contained metal, total 2.61 billion pounds (Blb) of copper equivalent (CuEq) at 0.44% CuEq, including 1.11 Blb of copper, 35.6 million pounds (Mlb) of cobalt, 1.41 million ounces (Moz) of gold, and 2.17 Moz of silver. (Table 1)337 Mt of Indicated Mineral Resources, expressed in contained metal, total 3.21 Blb of 0.43% CuEq, including 1.31 Blb of copper, 44.5 Mlb of cobalt, 1.81 Moz of gold, and 2.88 Moz of silver. (Table 1)509 Mt of Inferred Mineral Resources, expressed in contained metal, total 4.57 Blb of 0.41% CuEq, including 1.72 Blb of copper, 66.2 Mlb of cobalt, 2.77 Moz of gold, and 4.19 Moz of silver. (Table 1)Scandium Resource: The deposit hosts 609 Mt in the Measured and Indicated categories (containing approximately 17,510 tonnes of scandium) and 504 Mt in the Inferred category (containing approximately 14,465 tonnes of scandium). Scandium has been incorporated into the Mineral Resource Estimate and under current processing constraints, is limited to 12.5% of tailings using internally generated acid. The scandium resource is estimated at 76 Mt Measured and Indicated at 28.8 g/t Sc (containing 2,189 tonnes of scandium) and 63 Mt Inferred at 28.7 g/t Sc (containing 1,808 tonnes of scandium).Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 25, 2026) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce the update of the Mineral Resource estimate (MRE) of its 100%-owned polymetallic Hat porphyry project (Hat), in northwestern British Columbia. With major content of copper, gold, cobalt and silver, as well as scandium, Hat becomes an important source of critical minerals.Farshad Shirvani, president and CEO of Doubleview Gold Corp commented, "Year by year, the size of the deposit was increased by very targeted drilling, bringing it to a footprint of about 1.6 km by 1.6 km. I appreciate my technical and management team in this endeavour. We've discovered numerous additional elements within the Hat deposit that will soon be unveiled, each further showcasing the deposit's uniqueness and enhancing the resource."Summary of MRE for Hat Deposit:Table 1: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026,(Base-Case Scenario to be Presented in the Technical Report)Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(%)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.180.0080.372.611.111.4135.62.17Indicated3370.430.210.190.0080.393.211.311.8144.52.88Total M+I6090.430.210.180.0080.385.822.423.2280.15.05Inferred5030.410.180.190.0080.384.571.722.7766.24.19 Table 2: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US$4.80/lb Cu, US$20.00/lb Co, US$3,200/oz Au, US$46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C$7.93/t milled processing cost and C$2.90/t milled general and administrative cost, with a mining cost of C$3.01/t plus incremental mining cost increasing by C$0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.The block model is defined relative to a model origin at UTM Zone 9N 346,750 E / 6,453,000 N / 0 (NAD 83). Parent blocks measure 15 × 15 × 15 m, totalling 136 × 150 × 75 blocks across extents of 2,040 m (X), 2,250 m (Y), and 1,125 m (Z). All volumes and estimates are constrained by these discretization parameters. Figure 1: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 Kilotonne per Day (kt/d) Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_001full.jpgFigure 2: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 kt/d Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_002full.jpgFigure 3: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_003full.jpgFigure 4: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_004full.jpgThe Hat DepositThe Hat Claims property consists of 16 mineral tenures covering 13,823.09 hectares north of the Golden Bear mine road in northwest B.C. For additional information please visit www.doubleview.ca.Mineit Consulting Inc (Mineit) prepared the MRE in accordance with CIM Definition Standards on Mineral Resources and Reserves on Mineral Resources and Reserves. A Technical Report in support of the MRE will be filed on SEDAR+ (www.sedarplus.ca) within 45 days.Tomasz Wawruch, FAusIMM, of Mineit, is the Qualified Person for the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a geology and mineral resource consultant independent of Doubleview. Gilles Arseneau, PhD., P.Geo of ARSENEAU Consulting Services Inc. provided an independent peer review of the MRE and did not identify any fatal flaws with the resource model prepared by Tomasz Wawruch.With respect to the Hat Project metallurgical studies, EUR ING Andrew Carter, B.Sc., CEng., MIMMM QMR, MSAIMM SME, of Magister Metallurgy, is Doubleview's Qualified Person, as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects; he has reviewed and approved the technical contents of this news release. Mr. Carter is independent of Doubleview.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX-Venture Exchange (TSXV: DBG), the OTCQB (OTCQB: DBLVF), the Berlin Stock Exchange [GER: A1W038], and the Frankfurt Stock Exchange [1D4]. Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties—collectively critical minerals—and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285247 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀有限公司（1952.HK）宣佈，於2026年2月24日以線上虛擬會議形式舉行的股東特別大會順利召開，會議所提呈的全部決議案均獲股東正式通過。根據公告，本次股東特別大會批准、確認及追認了公司於2025年12月11日與海森生物簽署的商業化服務協議及其項下擬進行的相關交易，為公司後續商業化運營及業務推進提供支持。與此同時，大會還批准了向公司管理層授出獎勵安排，以及採納2026年股份計劃及相關授權限額等決議案。此次各項決議案的高票通過，體現了投資者對公司戰略方向及公司治理的認可，並將支持公司持續推進商業化佈局及長期發展戰略。雲頂新耀此前表示，與海森生物的合作有助於進一步提升現有商業化平台運營效率，加快產品全生命周期及全渠道覆蓋能力建設。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Exhibition space fully secured prior to the show, reflecting strong exhibitor confidence in Northern Vietnam’s laboratory and scientific markets- Over 150 international and local exhibitors & brands confirmed from USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam and China & more- Expanded Live Lab, following its debut in Ho Chi Minh 2025, now making its first appearance in HanoiHANOI, Vietnam, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) - analytica Hanoi 2026, the regional edition of the globally recognised analytica brand, will take place from 22–24 April 2026 at the International Centre of Exhibition (I.C.E), Hanoi. Tailored to the needs of Northern Vietnam's science and laboratory community, the exhibition space is fully secured ahead of opening, reflecting strong market demand and the growing importance of Vietnam as a laboratory and innovation hub."Northern Vietnam is rapidly emerging as a hub for laboratory innovation. With analytica Hanoi 2026, we are bringing the Live Lab to Hanoi for the first time, following its successful debut in Ho Chi Minh 2025. This demonstrates our commitment to connecting international solution providers with the region’s growing scientific and industrial community," said Michael Wilton, CEO and Managing Director, Messe Muenchen International Asia Pte, Ltd.Broad International Participation Reflects Market Relevanceanalytica Hanoi 2026 will feature over 150 exhibitors and brands from key laboratory and technology markets including USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam, Latvia, China etc. highlighting its strong global reach. This edition builds on the success of previous analytica Vietnam shows, offering a dedicated platform for technology exchange, business networking and market access tailored to Northern Vietnam.The exhibition will showcase laboratory instruments, analytical systems, biotechnology and diagnostics solutions, quality assurance technologies, and sustainable laboratory operations, meeting the evolving needs of the region’s laboratory and research sectors.Live Lab Makes Its Northern DebutFollowing its successful debut at analytica Vietnam Ho Chi Minh 2025, the Live Lab is coming to Hanoi for the first time in 2026. This interactive zone allows exhibitors to present hands-on demonstrations of laboratory technologies and real-world applications, enabling visitors to directly experience workflows, assess performance, and explore practical solutions.By bringing this pioneering format to Northern Vietnam, analytica Hanoi 2026 provides a first-of-its-kind experiential platform in Hanoi, offering laboratory professionals, researchers, and industrial users a unique opportunity to engage with both international and local technology providers in a practical, applied setting.Northern Vietnam Strengthens Its Role as a Growth MarketNorthern Vietnam is a key driver of Vietnam’s science and technology-led industrial upgrading, with strong investment across pharmaceuticals, healthcare, electronics, food safety, environmental monitoring, and advanced manufacturing. These sectors underpin national priorities on innovation, quality infrastructure, and sustainable growth, increasing demand for advanced laboratory technologies and digitalised operations.Building on this momentum, analytica Hanoi 2026 supports national science & technology objectives as a platform for knowledge exchange, standards alignment, and technology adoption.The event features a two-stage programme. The Academic Conference, jointly organised by Messe München, the Vietnam Analytical Sciences Society (VASS), VNU University of Science (HUS) – Vietnam National University, and VNEES, contributes to knowledge advancement and talent development in priority fields including green and environmental chemistry, food safety and quality control, semiconductor manufacturing, and molecular biology applications in biopharma and pharmacogenomics. The Technical Forum reinforces quality infrastructure and regulatory readiness, addressing ISO/IEC 17025, GLP, the laboratory outlook for 2026–2030, and applied seminars, complemented by exhibitor technology sessions.A Trusted Platform for Business and KnowledgeThe full occupancy of exhibition space underscores analytica Hanoi’s role as a reliable platform linking global technology providers with Northern Vietnam’s laboratory and research community. Confirmed exhibitors include WESTINGAREA, WIGGENS, GL SCIENCES, BCE, CHC LAB, DAIHAN SCIENTIFIC, ANTON PAAR, KIMTECO, LECO VIETNAM, GLASS TAO, FOSS VIETNAM, HTI SCIENTIFIC, MERCK VIETNAM, UNITEK and many more.Supporting programmes such as live demonstrations, hosted buyer engagements, and structured business matching further enhance opportunities for business development and collaboration.REGISTRATION NOW OPENanalytica Hanoi 2026 is expected to attract laboratory professionals, researchers, manufacturers, distributors, and institutional representatives from across Vietnam and the region.Visitor registration is now open:https://registration.analyticavietnam.com.vn/en/reg/analytica-vietnamFor more information, please visit www.analyticavietnam.comor contact analytica Vietnam via email analyticavietnam@mmiasia.com.sgAbout analytica Hanoi 2026analytica Hanoi is the official regional spinoff of analytica Vietnam, strategically developed to meet the rising demand for laboratory and analytical solutions in northern Vietnam. As the region experiences accelerated growth in research, healthcare, and industrial sectors, analytica Hanoi 2026 offers a focused platform for companies aiming to tap into this dynamic and fast-emerging market. The upcoming exhibition is set to take place from April 22 to 24, 2026 at the International Centre of Exhibition (I.C.E), 91 Tran Hung Dao, Hanoi, Vietnam.About analytica Vietnam 2027analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from March 31 to April 2, 2027 at the Saigon Exhibition and Convention Center (SECC), 799 Nguyen Van Linh, Ho Chi Minh City, Vietnam. More details can be found here.About analytica worldwideFor over five decades, analytica has been the leading international trade fair series for laboratory technology, analysis, and biotechnology. Organized by Messe München, the series includes analytica in Munich, analytica China, analytica Anacon India, analytica USA, analytica Vietnam, and now, analytica Hanoi. Additional information about these exhibitions and their programs of events is available at www.analytica.de.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of world-leading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.com.About Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twe lve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Siegli L. BacudioProject Managersiegli@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Shae NguyenMarketing Executiveshae@analyticavietnam-exhibitions.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽支持《2026-27年度財政預算案》（《財政預算案》）中提出有關跨境安老、落實《香港可持續披露準則》以及積極推動體育普及化、盛事化的多項舉措。周大福人壽執行董事兼行政總裁葉文傑表示：「作為扎根香港40年的保險公司，周大福人壽持續創新產品，並不斷擴展中國內地與香港兩地醫療服務網絡等安排，以配合政府支持跨境安老的措施。在可持續發展方面，我們與政府抱持共同願景，早前自願發佈符合本地及國際披露標準的ESG報告，未來亦會繼續將可持續發展融入業務策略。在體育盛事化方面，我們將以啟德體育園獨家創始保險合作夥伴的身份，支持政府推動香港體育普及化及盛事化發展，以及未來體育精英的培育，開創保險新價值。」他續稱：「同時，周大福人壽歡迎《財政預算案》中優化保險公司風險為本的資本制度，以及逐步推行強積金『全自由行』等舉措，從而提升市場信心及整個保險業界的專業水平。」持續優化跨境安老服務《財政預算案》提出支持跨境安老，包括「廣東院舍照顧服務計劃」本月起新增至26家，覆蓋大灣區內地9個城市。周大福人壽相信這些舉措有助改善醫療及安老服務配套，公司除了在產品中加入中國內地與香港兩地醫療服務保障覆蓋，今年初更進一步擴展「直接支付服務」網絡至多個大灣區城市的公私營醫院。未來周大福人壽將持續優化醫療保險產品及服務體系，為北上南下客戶提供更貼合生活需要的方案。積極推動綠色金融發展為配合政府鞏固香港國際綠色金融中心地位，周大福人壽一直將可持續發展融入業務策略。今年1月，公司自願發佈獨立環境、社會及管治（ESG）報告，是領先業界的舉措。此舉與政府落實《香港可持續披露準則》、推動跨界別合作的願景一致，我們將合力推動綠色金融發展。致力培育體壇新星《財政預算案》中提及政府將積極推進體育普及化、精英化、盛事化、專業化和產業化，並爭取舉辦更多大型國際體育賽事和活動。作為啟德體育園的獨家創始保險合作夥伴，周大福人壽將與啟德體育園加強合作，公司去年開始冠名贊助飛越啟德「小劍神」培訓計劃，與政府文體旅發展策略相輔相成，同時發揮協同效應，繼續支持新晉運動員邁向國際，成就未來世界冠軍。關於周大福人壽周大福人壽保險有限公司（「周大福人壽」）扎根香港40年，為周大福創建有限公司（「周大福創建」）（香港股份代號：659）的全資附屬公司，也是香港最具規模的壽險公司之一。作為周大福企業成員，周大福人壽緊扣鄭氏家族（「周大福集團」或「集團」）生態圈的雄厚資源，致力為客戶及其摯愛於「生活、成長、健康、傳承」的人生旅程中，提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局，周大福人壽矢志成為亞太區領先的保險公司，持續開創保險新價值。周大福人壽保險有限公司（於百慕達註冊成立之有限公司） Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (HKTDC) welcomes the 2026–27 Budget delivered this morning by the Financial Secretary of the Hong Kong Special Administrative Region (HKSAR), Paul Chan. The Budget reflects the HKSAR Government’s determination and proactive approach to growing the economy, driving development and improving people’s livelihoods. It focuses on strengthening Hong Kong’s status as an international centre for financial, trade, shipping and I&T, while accelerating new industrialisation and digital transformation.The Budget also supports enterprises in integrating into the country’s overall development and seizing opportunities under the 15th Five-Year Plan. This includes continuously improving the business environment, promoting artificial intelligence and green sustainable development, as well as implementing various measures to consolidate Hong Kong’s unique advantages in connecting the Chinese Mainland and the world.Prof Frederick Ma, Chairman of the HKTDC, said: “The HKTDC welcomes the forward-looking measures in the Budget, including the announcement of the city’s first five-year plan and injecting HK$200 million into the BUD Fund. These initiatives demonstrate the HKSAR Government’s commitment to supporting Hong Kong SMEs and facilitating economic transformation and high-quality development. We will actively align with the Government’s policy direction, implement the national 15th Five-Year Plan, and support Hong Kong in consolidating and enhancing its position as an international financial, shipping and trading centre, while establishing the city as an international hub for I&T and high calibre talents.We will also extend our global business network, further deepen our ties with the ASEAN and Middle Eastern markets and explore more emerging markets. These efforts will further enhance Hong Kong’s pivotal role in the Belt and Road Initiative.”Prof Ma added: “As a superconnector and super value-adder, Hong Kong enjoys the unique edge of linking the mainland and global markets. We successfully bring in international capital, technology, talents and advanced management expertise, helping mainland and local enterprises upgrade and innovate, while supporting mainland companies to go global via Hong Kong’s professional services platform.“As a core member of the GoGlobal Task Force, the HKTDC will further leverage its network of 51 offices worldwide to help businesses explore global markets, diversify risks and achieve growth. We will continue to provide value-added services to Hong Kong enterprises, especially SMEs, empowering them to capitalise on e-commerce opportunities, drive their digital transformation and enhance their competitiveness.”Comprehensive Go-Global Support ServicesThe HKTDC will strengthen its diverse business platforms, including international exhibitions, conferences, business matching, market intelligence and e-commerce support, offering one-stop comprehensive go global assistance, covering brand promotion, supply chain management, professional services matching and risk management.The HKTDC will roll out more concrete measures and support programmes to help Hong Kong and mainland enterprises capitalise on national development strategies and global market opportunities and expand their international business in a sustainable manner.Strengthening I&T ecosystem to help enterprises capture opportunitiesThe Budget introduced a range of measures to promote Hong Kong’s development as an international I&T hub. The HKTDC will continue to actively support the HKSAR Government by integrating I&T elements into its exhibitions, conferences and events. These platforms will help promote Hong Kong’s I&T strengths and ecosystem advantages to mainland and overseas markets, foster cross-industry and cross-regional collaboration and incorporate IP elements to enhance overall competitiveness and effectively protect innovation outcomes.As the flagship event of the Business of Innovation and Technology Week (BIT Week) jointly organised by the Innovation, Technology and Industry Bureau of the HKSAR Government and the HKTDC, InnoEX will once again take place in April to showcase cutting-edge technologies and global innovations, as well as accelerate technology commercialisation and achieve sustainable growth.The HKTDC will continue to leverage Hong Kong’s unique advantages as a global business hub, using its flagship events, efficient business matching and professional service connections to support businesses expand internationally.The Budget also notes that the Asian Financial Forum (AFF) will celebrate its 20th anniversary next year. The HKTDC will work closely with the HKSAR Government to further strengthen AFF’s focus on finance empowering business (Finance +), by leveraging on the Global Business Summit, to enable the financial sector to better serve the real economy and industries with a competitive edge.Media enquiriesHKTDC’s Communications & Public Affairs Department:Agnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 2026年2月2日，維昇藥業於上海舉辦維臻高(R)（注射用隆培生長激素）獲批上市投資者交流會。 該產品已於1月26日獲得國家藥品監督管理局批准上市。公司在會上表示，維臻高(R)被定位為具備里程碑意義的創新產品 - 不僅是首個在歐美獲批用於兒童的長效生長激素，也是目前臨床研究中唯一被證實在療效上優於日製劑的長效生長激素產品。在生長激素賽道中，隨著多款產品陸續納入醫保、價格體系快速下探，市場競爭格局正在發生變化。維昇藥業以臨床價值和技術壁壘為核心，打造差異化的高端產品路徑。本次交流會由公司管理層系統介紹了產品研發邏輯、臨床數據及當前階段商業化策略的核心思路。本次會議邀請了多位合作夥伴與行業嘉賓出席，包括國婦嬰主任醫師餘文教授、安科生物高級副總裁姚建平先生、副總裁鮑學科先生、上藥控股副總經理宋潞潞女士、上海和睦家醫院長寧院區執行院長劉曉龍先生等到場支持。同時，公司長期股東代表——碧沃投資合夥人柳丹先生亦出席交流，體現了核心股東對公司商業化路徑與長期價值的持續認可。中信證券、東吳證券、天風證券和國海證券等多家大型券商及投資機構亦參與本次會議。一、產品內核：技術壁壘構建差異化護城河1.1 "暫時連接"技術的獨特性在生長激素領域，由於技術壁壘高，實現長效化與保持活性分子的天然結構長期被視為"魚與熊掌不可兼得"，而維臻高(R)的研發上市成功突破這一行業技術壁壘，是全球首款實現"長效化+天然結構"作用機理的長效生長激素。維昇藥業首席商務官陳軍在會上詳細拆解了TransCon技術平臺的突破：通過惰性載體（PEG）將天然結構的重組人生長激素暫時包裹和保護起來形成前藥，前藥在注射至皮下時沒有活性，進入血液迴圈在，將惰性載體與生長激素暫時連接起來的TransCon連接結構在體溫與生理pH值下發生自動裂解，7天內以特定的速率逐步釋放出與人體自身分泌完全一致的2.2萬道爾頓（22kD）、191個氨基酸的天然結構的生長激素。這一"暫時連接"機制與市面上其他長效生長激素的"永久連接"形成本質區別。陳軍指出，目前已上市的其他長效生長激素均屬於"生長激素類似物"——其活性分子結構已改變，分子量高達6萬-9萬道爾頓，遠遠高於天然生長激素的2.2萬道爾頓。維臻高(R)進入人體內釋放的活性分子與內源性生長激素的分子量、分子結構、組織分佈以及藥理特性相同，也是首款活性分子是"長效生長激素"而非"生長激素類似物"的長效產品。國婦嬰主任醫師餘文教授從臨床角度補充了關鍵細節：分子量過大的藥物難以穿透緻密的骨骺板，無法發揮生長激素的直接作用，也就可能直接影響療效。維臻高(R)以內源性生長激素的"原藥形式"發揮作用，是其頭對頭研究取得優效結果的理論依據和科學基礎。1.2 說明書上的"法律證據"餘文教授在交流中特別強調，在臨床實踐中，尤其是一款新藥，經國家藥監部門審評並寫入藥品說明書的內容，是判斷藥品療效與安全性的核心法定依據，也是臨床用藥的權威規範標準，它構成了療效與安全性判斷的核心標準,是藥品的"身份證"。維臻高(R)本次獲批的產品說明書直接顯示了其療效優於每日製劑：境外臨床研究結果："主要療效終點是第52周時年化生長速率（AHV）。本品治療52周時的AHV非劣效並優效於健豪寧(R)組。此外，本品治療後的身高SDS較基線的增加幅度高於健豪寧(R)組。從治療第26周至第52周試驗結束時，對於AHV和身高SDS 較基線的變化，本品組都較健豪寧(R)組更顯著。"中國臨床研究結果："主要療效終點是第52周AHV。本品治療52周的AHV為 10.66cm/年，相比諾澤(R)組的AHV 9.75cm/年，統計分析結果顯示達到非劣效性以及優效性，即證明了本品治療的52周AHV優效於諾澤(R)組，與境外3期研究結果一致。此外，本品組治療時的身高SDS較基線的增加幅度高於諾澤(R)組，也顯示了優效性。從治療第13周至第52周試驗結束時， 對於AHV和身高SDS較基線的變化，本品組都較諾澤(R)組更顯著。"1.3 安全性設計的雙重保障分子安全性：由於維臻高(R)的活性成分與內源性生長激素結構完全一致，避免了未知分子風險；而其他長效生長激素均為"人造分子"，長期安全性存疑（輝瑞、諾和諾德曾嘗試PEG永久修飾技術研發長效生長激素，但均因安全性和療效問題終止研發）。局部安全性：注射部位無活性，避免脂肪萎縮等不良反應。陳軍特別解釋：其他部分長效產品將"7天劑量一次打入一個注射部位"，注射部位存在高濃度活性成分；維臻高(R)的"包裹"技術使其在皮下無活性，只在該發揮作用時才呈現活性，降低了導致脂肪細胞溶解、皮膚凹陷的可能，這是"另一個安全性優勢"。更值得關注的是其長期安全性數據：維臻高(R)全球關鍵3期研究治療1年的結果顯示，其不良反應發生的種類與頻率均與生長激素日製劑相似；而在治療時間最長達6年的延長期研究中，維臻高(R)也未出現與生長激素日製劑不同的、新的不良反應類型。餘教授談到，生長激素日製劑在生長激素缺乏症患兒中已有超過40年的使用經驗，其安全性特已被臨床醫生熟知並掌握，基於明確的研究數據，維臻高(R)與日製劑一致的安全性表現，顯然也為醫生的應用提供了更充分的保障。1.4 儲存與使用的便利性突破維臻高(R)在不含防腐劑情況下，室溫（≤30℃）可儲存6個月，在2-8℃條件下可存儲5年，是唯一可在室溫下長期存放的生長激素。餘文教授強調："這是我們當時完全沒有想到的效期，並且清楚的寫在說明書中。"這一特性對需要攜帶藥物出行、參加夏令營的家庭至關重要。1.5 注射體驗的創新設計維臻高(R)配備電子自動注射筆，由Phillips-Medisize公司生產，2022-2023年獲歐洲和美國三項工業設計大獎（PDA 藥物遞送創新獎、PharmaPack 給藥與包裝創新獎、紅點工業設計獎）。其特點包括：- 單按鈕開關，藥物複溶與注射全自動完成- 隱形針頭設計，患兒看不到針，減少心理恐懼- 配合固定劑量雙腔預充筆芯，注射前無需調節劑量，同時避免浪費- 每月4支筆芯+6支針頭的一體化包裝二、市場策略：技術與臨床優勢下的差異化商業路徑2.1 定價邏輯：突出產品差異化，以技術優勢形成產品價值優勢維昇藥業首席商務官陳軍表示：維臻高(R)的年治療費將會於產品上市時最終確定，但一定會顯著高於其他長效生長激素納入醫保後的價格。但這一定價並非簡單的"高端溢價"，而是基於三重錨定：- 價值錨定：產品具備"天然結構+優效+室溫保存"三重獨特屬性，維臻高(R)作為長效生長激素迭代產品，產品的獨特優勢賦予了其核心定價權，將填補高端市場的真空。- 國際錨定：該產品在歐美獲批上市，美國年治療費用50-60萬元，維臻高(R)以其"技術優勢+臨床優勢+歐美品質"為背書，將臨床需求和價值錨點與國際接軌。- 長期健康價值錨定：生長激素治療具有明確的時間窗口和長期獲益特徵。其價值並不取決於單一年度的費用比較，而在於對終身身高結局、心理健康與社會功能的長期改善。從全週期視角衡量，該治療所帶來的健康收益與成本投入之間具有清晰、可解釋的價值邏輯。這一策略的風險在於支付能力，但維昇藥業的判斷是：生長激素市場90%以上為自費，80%以上銷售發生在私立醫院。2.2 管道佈局：合縱連橫的"作戰地圖"維昇藥業作為初創企業，選擇了"輕資產、重合作"的擴張路徑：- 推廣端：與安科生物強強聯手，其高級副總裁姚建平表示，公司在生長激素領域深耕27年，以學術觸達95%的生長激素KOL專家。此次與維昇藥業的合作，"27年經驗+劃時代產品"將形成前所未有的商業化佈局。雙方將按地域區隔運營，維昇藥業自營沿海核心市場，安科生物負責其餘廣闊區域，實現市場的全面覆蓋。- 流通端：上藥控股作為進口分銷平臺，依託其成熟的供應鏈體系，提供從通關到終端的全程服務。上藥控股副總經理宋潞潞指出，維臻高(R)是其經銷的大分子生物藥中，唯一不含防腐劑且可常溫保存6個月的產品，"這兩個優勢在對藥品商業化成功，特別是兒童用藥的商業化成功方面，至關重要"。- 診療端：與和睦家、小蘋果、卓正等高端私立醫院建立深度合作，構建"篩查-診療-管理"的全流程閉環。上海和睦家醫院長寧院區執行院長劉曉龍表示，其患者群體對"技術領先、長期安全"的產品需求明確，維臻高(R)的核心優勢與該群體需求高度匹配，具備良好的臨床土壤。- 流量端：患者及家庭在疾病認知與治療決策過程中，主要通過內容社區、AI 搜索工具及合規的互聯網醫療平臺獲取相關科普資訊，逐步形成以專業性、可及性和合規性為核心的患者資訊入口，讓優質醫療資訊精准觸達目標人群。三、團隊建設：用近乎苛刻的標準篩選最強執行者維昇藥業銷售與商業運營副總裁潘海風詳細介紹了團隊建設的"高強度、嚴標準"體系：- 招聘標準：一線商業化團隊中，約20%具備碩士學歷，80%為醫藥相關本科背景；近三分之一來自其他公司的地區經理級別，整體商業化人員結構和行業經驗顯著高於行業平均水準。- 考核機制：全員"日考+周考+月考"，內容涵蓋產品知識、競品知識、臨床醫學、疾病知識；每日考試須達90分以上，集訓落地考不合格者原機遣返，以嚴苛的考核標準保障團隊的專業能力，確保用人標準與產品價值相一致。- 提前佈局：公司提前規劃、前置投入，產品上市前6個月商業化團隊已90%到崗，為產品上市後的快速市場推進做好了充分準備，體現出公司對商業化執行的前置投入與系統規劃。四、其他Q&A環節：問題一：在目前的定價水準下，維臻高(R)的利潤率表現如何？未來隨著地產化推進，盈利空間如何展望？ 回答： 公司堅持"先上市、先可及"的策略，進口階段的毛利率足夠產品上市早期的推廣。隨著兩年多後實現地產化生產，即便在當前價格水準大幅下降的情況下，毛利率仍有望達到80%以上。從進口到地產化的路徑清晰，隨著市場規模的持續放量，盈利能力將隨規模放量持續改善。問題二：維臻高(R)在公立醫院與民營醫院中的銷售場景如何落地？在部分長效生長激素已進入國談的背景下，公司如何發揮差異化優勢？ 回答： 公司將覆蓋三類管道：公立醫院院內、公立醫院處方外配及民營醫院。受國談因素影響，公立院內並非未來主戰場，核心增長將來自處方外配及民營醫療體系。同時，國家層面已明確提出要有序推進醫師多機構執業，鼓勵醫師依法開展多點執業，醫生在公立醫院與民營醫療機構之間的執業流動性持續提升。這一趨勢為創新、差異化產品在院外及民營場景中的推廣和規範使用創造了有利條件。公司將基於這一制度環境，在所有合規場景中積極佈局。問題三：除維臻高(R)外，公司其他管線在未來幾年的上市節奏及協同貢獻如何？ 回答： 公司在內分泌領域已佈局多條管線，其中針對甲狀旁腺功能減退的帕羅培特立帕肽已分別於2024年年初和年底在歐盟跟美國獲批；第三個品種那韋培肽這個月底迎來其 PDUFA 日期，後續產品在中國的上市節奏有望加快。多產品協同放量後，公司整體規模有望持續躍升，長期目標是打造內分泌與代謝領域具備國際競爭力的百億級創新藥企。問題四：已使用短效生長激素的患者，是否可以無縫切換至維臻高(R)？是否有相關臨床證據支持？ 回答： 國際3期試驗有一個關於日製劑轉換為隆培生長激素的研究。研究顯示，對於平均使用日製劑已有1.14年、平均劑量為0.29 mg/kg/周的患者，轉為隆培生長激素0.24mg/kg/周後，仍然保持了非常良好的追趕生長的趨勢。這一研究結果證明了由日製劑轉為隆培促生長素每週一次治療仍可保持非常良好的生長趨勢和療效。問題五：維臻高(R)在長期使用方面的療效和安全性表現如何？ 回答： 在國際3期試驗的延長期實驗中，患者平均治療4.3年、最長達6年，期間患者身高持續改善，部分患者最終身高SDS甚至超過父母平均身高SDS，充分體現了產品在長期治療中的有效性、安全性及穩定性。問題六：公司目前商業化團隊建設情況如何？與安科生物的合作如何推進？ 回答： 公司首年商業化團隊已基本到位，團隊人員以業內資深骨幹為主，強調高專業度、強培訓與嚴格考核。區域運營上，維昇負責沿海一線重點城市，安科覆蓋其他區域，雙方執行統一學術與培訓標準，形成"強強聯合"的銷售體系，共同推進產品的市場落地。五、長期展望：從單一產品到平臺價值維昇藥業執行董事兼首席執行官盧安邦在交流結束的致辭中描繪了公司長期發展的藍圖：維臻高(R)的獲批意味著TransCon技術平臺繼FDA和EMA後獲NMPA認可，為後續產品鋪平道路。在研的帕羅培特立帕肽（甲狀旁腺功能減退症）2024年美歐獲批後首年銷售近40億人民幣，那韋培肽（軟骨發育不全）針對中國1萬患兒的治療剛需。"2026-2028是公司"十年磨一劍"的決戰期，"盧安邦表示，"我們要驗證從臨床、註冊、准入到商業化的端到端能力，最終成為內分泌代謝領域的百億級領軍企業。"本文基於2026年2月2日維昇藥業投資者交流會紀要整理，內容僅供資訊參考，不構成投資建議。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 今日，市場關注到首程控股（00697.HK）股價出現一定波動，疊加個別股份變動安排，引發部分投資者討論。綜合公司近期公告、公開行情數據及市場結構變化情況來看，相關波動更多體現為階段性資金博弈。在資本結構持續優化、產業主線邏輯清晰的背景下，公司基本面未發生實質性變化。市場人士透露，在近期市場調整過程中，部分國際長線資金通過協議及大宗方式完成戰略性布局，實現了籌碼結構的有序轉換。相關觀點認為，這種「短期籌碼向長期資本轉移」的過程，有助於平滑階段性流動性波動，同時提升股東結構的穩定性與質量。從資金屬性看，長線資本的進入往往意味著對公司中長期成長路徑與價值兌現能力的認可，為後續估值修復奠定更加堅實的資金基礎。從資本市場運行規律來看，當企業戰略轉型逐步進入成果兌現階段時，股東結構的優化與再平衡往往同步發生。本輪結構調整所釋放的核心信號在於，國際資金正以更為積極的姿態參與公司成長進程，認可其由傳統資產管理平台向「硬科技產業生態構建者」升級的戰略方向。這種資本與產業邏輯的共振，有助於強化市場對公司長期價值的認知與定價信心。外資機構的逆勢買入，其邏輯支撐源於首程控股基本面的深刻蛻變。公司正從傳統的資產管理平台，成功向「產業生態構建者」轉型。通過獨特的「資本 + 場景 + 運營」三維模式，首程控股已構建起閉環生態，特別是在機器人賽道的前瞻性布局，已使其成為港股硬科技投資的標杆。2026年被市場普遍視為具身智能與人形機器人商業化加速落地的重要時間窗口。首程控股前期在機器人賽道的系統性布局，正在進入集中收穫期，機器人賽道整體投資回報表現亮眼：核心項目實現高溢價。依托對自變量科技、宇樹科技等領軍企業的早期重倉，已實現顯著帳面增值。隨著宇樹科技等明星項目正式開啟IPO衝刺，首程控股持有的股權將迎來從「帳面浮盈」向「現金分紅」的實質性跨越，持續增厚上市公司利潤。此外，值得關注的是，在2026年馬年央視春晚舞台上，宇樹科技、銀河通用、松延動力等機器人企業集體亮相，展示了具身智能技術在複雜動作控制與人機交互方面的突破。這不僅強化了公眾認知，也標誌著相關企業已進入規模化應用前夜。作為上述企業的重要早期布局方，首程控股間接受益於產業熱度與商業化進程提速帶來的估值重估。市場分析人士表示，今日的市場交易將促使公司股東結構更趨多元化。國際長線資金的進入，一方面提升了股票的全球流動性基礎與治理透明度預期，另一方面也為未來產業擴張提供更廣泛的資源協同空間。從市場經驗看，當企業基本面處於上行周期且結構性不確定性逐步消除時，股東結構的優化往往成為估值修復的重要觸發因素。分析人士指出，本輪籌碼調整本質上是資本結構的戰略再平衡，為公司進入價值兌現周期掃清短期供給壓力。綜合來看，首程控股當前處於三重拐點疊加階段。首先是產業拐點——具身智能與機器人商業化加速；其次是資本拐點——投資項目進入集中兌現期；再次是結構拐點——國際長線資本入場優化股東結構。在國際資金認可與產業價值紅利共振之下，公司估值邏輯正從「傳統資管估值框架」向「硬科技產業平台估值框架」切換。隨著產業落地與資本回報逐步兌現，市場對於首程控股作為「智能時代產業基礎設施構建者」的認知將進一步強化，其長期價值重塑進程或已進入實質性階段。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 2月23日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK））宣布，已正式獲得香港證券及期貨事務監察委員會（SFC）批准，自2026年2月12日起可在其兩家持牌機構（國泰君安證券（香港）有限公司及國泰君安外匯有限公司）采用國際掉期與衍生工具協會ISDA標準初始保證金模型（Standard Initial Margin Model, "SIMM" ）計算場外衍生品交易的初始保證金。ISDA SIMM 是業界通用的標準方法論，專門用于計算非集中清算衍生品的監管初始保證金。該模型通過建立統一的計算標準，使所有市場參與者得以遵循同一框架進行保證金核算，不僅避免了各機構獨立開發模型所産生的額外成本，還有效减少了因算法差异引發的潜在爭議。其配套的治理框架進一步確立了行業共同實踐，確保保證金計提既符合全球監管要求，又充分保障了保證金的充足性。此次獲批標志著國泰君安國際場外衍生品業務的風險管理能力邁上新台階，在鞏固合規與風控標杆的同時，顯著提升中資券商國際化競爭力。通過采用國際市場通行的SIMM模型，公司得以接軌國際大行標準，能够更精准、高效地管理初始保證金，在有效控制交易對手風險的同時，顯著節省交易成本，實現更高資本效率，增强與全球機構對手方的合作信任，從而提升業務的長期競爭力。此次獲批不僅是對公司衍生品業務技術實力的認可，更是監管機構對公司內部控制、尤其是風險管理能力的又一里程碑式肯定。展望未來，國泰君安國際將進一步精進衍生品業務的內控管理體系，築牢長遠穩定發展的根基。同時，作爲香港資本市場的重要一員，公司將一如既往地配合監管機構，深度參與市場基礎設施建設，助力提升香港場外衍生工具市場的國際競爭力與活力。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）已於2026年2月24日獲得中國國家藥品監督管理局（NMPA）受理磷酸蘆可替尼乳膏（「產品」）輕中度特應性皮炎（「AD」）的新藥上市許可申請（NDA）。產品擬用於其他外用藥控制不佳或不建議使用時，非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非持續性慢性治療。且該項NDA因「符合兒童生理特徵的兒童用藥品新品種、劑型和規格」，已獲得NMPA藥品審評中心批准納入優先審評品種名單，有望加快產品AD適應症上市審評進程。特應性皮炎III期臨床數據亮眼，優先審評加速上市磷酸蘆可替尼乳膏已於2026年1月獲得NMPA批准上市，成爲中國批准的首款且唯一用於白癜風治療的靶向藥。此次增加AD適應症NDA獲受理，是產品向多治療領域拓展的關鍵里程碑。磷酸蘆可替尼乳膏已在輕中度AD的一項隨機、雙盲、安慰劑對照中國三期藥物臨床研究取得積極結果：- 療效優異：產品成功達到主要終點，即使用產品治療8周，達到研究者整體評估（IGA）評分為0或1分，且較基線改善≥2分的受試者比例，顯著高於安慰劑（63.0% vs 9.2%，P

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康希諾生物（688185.SH/06185.HK）宣佈，公司自主研發的ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）——曼海欣(R)擴大適用人群的補充申請已正式獲得國家藥品監督管理局批准。此次獲批後，曼海欣(R)適用於3月齡至6周歲（83月齡）的嬰幼兒及兒童，用於預防由A、C、Y、W135群腦膜炎奈瑟菌引起的流行性腦脊髓膜炎（以下簡稱"流腦"）。此次曼海欣(R)擴齡獲批，具有重要的公共衛生和商業發展意義。一方面，在我國現行免疫規劃程式中，6歲是入學前流腦疫苗接種"最後一針"的重要節點，長期以來，國內針對3歲以上兒童的多價流腦結合疫苗選擇相對有限。曼海欣(R)此次擴齡獲批，為學齡期兒童提供了四價流腦多糖結合疫苗接種選擇，有助於填補兒童流腦防控在關鍵年齡階段的保護空白，進一步完善我國流腦免疫屏障。另一方面，適用人群範圍的擴大，將有助於曼海欣(R)進一步釋放產品潛力，提升商業化空間，並為該產品在國際市場的推廣與佈局奠定更為堅實的基礎。值得一提的是，康希諾生物日前已發佈2025年度業績預告，全年營收預計10.4–10.8億元，同比增長22.88%-27.61%；歸母淨利潤預計2450萬–2900萬元，將實現扭虧為盈。同時，公告明確指出，"公司持續踐行以創新為核心、以商業化落地為重點的發展戰略，中國首款四價流腦結合疫苗曼海欣(R)收入保持持續增長"。這也意味著康希諾生物已進入創新疫苗商業化收穫期。依託獨家技術平台、領先優勢及加速的國際化佈局，曼海欣(R)擴齡不僅鞏固了市場競爭力，也為康希諾生物的可持續增長注入新的動力。隨著產品覆蓋和國際拓展的推進，公司長期價值將開啟更廣闊的發展空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com